Clinical trial
Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease…
NCT00441155 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00441155 |
|---|---|
| Title | Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib |
| Official title | An Extension to a Phase I Multicenter, Dose Escalation Study of Nilotinib in Combination With Imatinib on a Continuous Daily Dosing Schedule in Adult Patients With Imatinib-Resistant Gastrointestinal Stromal Tumors (GIST) |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Gastrointestinal Stromal Tumors |
| Intervention type | Drug |
| Interventions | Nilotinib, Imatinib |
| Enrollment | 14 |
| Start date | Nov 1, 2006 |
| Primary completion | Jan 1, 2011 |
| Completion | Jan 1, 2011 |
| First posted | Feb 28, 2007 |
| Last update posted | May 13, 2013 |
| Countries | France, Italy, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: